AstraZeneca PLC is 167.7x more valuable than Rapport Therapeutics, Inc. by market capitalization ($286.27 B vs $1.71 B). Every figure below comes from audited SEC filings and refreshed market data.
| Metric | RAPP | AZN |
|---|---|---|
| Market cap | $1.71 B | $286.27 B |
| US-listed rank | #2225 | #45 |
| Net income (latest FY) | -$111.48M | - |
| SEC filings | 197 | 1,004 |
AstraZeneca PLC is 167.7x more valuable than Rapport Therapeutics, Inc. by market capitalization ($286.27 B vs $1.71 B).
Full pages: Rapport Therapeutics, Inc. and AstraZeneca PLC, or browse the full rankings.